LAB vs PSA · rev $174.4M vs rev $4.82B
Standard Biotools Inc (LAB) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
PSA (PSA) common stock.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
LAB currently screens at market cap $317.1M. PSA currently screens at market cap $0.
Not investment advice. Open the LAB and PSA stock pages for the full models.
Not investment advice.